INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2016

Analysis of orlistat trials found that published papers reported only 3% to 33% of investigator-reported adverse events due to post hoc filters.

Researchers analyzed 8,716 pages of clinical study reports (CSRs) and protocols from seven randomized placebo-controlled trials of orlistat (4,225 participants) and compared them with published papers. Only 3% to 33% of investigator-reported adverse events appeared in publications due to post hoc filters, despite six of seven papers claiming all adverse events were recorded. In one trial, orlistat-treated participants experienced significantly more days with adverse events than placebo (22.7 d vs. 14.9 d, p < 0.0001) and more severe events, details omitted from CSRs and publications. A key limitation is that the analysis was restricted to one drug tested in the mid-1990s, which may not apply to newer drugs.

Study type
Document analysis of clinical study reports, protocols, and publications
Who was studied
4,225 participants across 7 randomized placebo-controlled trials of orlistat
What was measured
Reporting and summarization of adverse events across protocols, CSRs, and papers

THE PAPER

Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis.

Schroll JB, Penninga EI, Gøtzsche PC. PLoS Med, 2016.

PubMed 27529343 ↗DOI 10.1371/journal.pmed.1001526 ↗

Gut & microbiomeWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.